Open AccessTreatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy
Author(s) -
Neill Duncan,
Ajay Dhaygude,
Jane Owen,
Thomas Cairns,
Megan Griffith,
A.G. McLean,
Andrew J. Palmer,
David Taube
Publication year - 2004
Publication title -
nephrology, dialysis, transplantation/nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfh536
Subject(s) - medicine , focal segmental glomerulosclerosis , ciclosporin , tacrolimus , renal function , urology , nephrotic syndrome , gastroenterology , urinary system , calcineurin , glomerulosclerosis , glomerulonephritis , proteinuria , surgery , transplantation , kidney
Focal segmental glomerulosclerosis (FSGS) commonly presents with nephrotic syndrome (NS), and spontaneous remission is rare. NS is a poor prognostic marker for renal survival, and has serious extra-renal complications. Rapid remission using drugs with minimal side effects is desirable. Tacrolimus (Tac) has a more potent immunosuppressive effect and may be less toxic at therapeutic doses than ciclosporin (CsA). Although CsA has a role in the treatment of FSGS, there are limited data regarding the use of Tac monotherapy in this setting, and this is limited to experience in children.